Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Acrux Limited

Market Cap 7.7M 5.44M 4.7M 4.32M 4.06M 7.63M 514M 51.16M 19.92M 252M 20.43M 19.99M 872M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 10.47M 7.4M 6.39M 5.87M 5.53M 10.38M 699M 69.57M 27.09M 343M 27.78M 27.19M 1.19B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 week-16.67%
Current month+25.00%
1 month+50.00%
3 months+25.00%
1 week 0.01
Extreme 0.014
0.02
1 month 0.01
Extreme 0.009
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.16
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 31/05/2025
Director of Finance/CFO - 20/06/2021
Chief Tech/Sci/R&D Officer - 14/02/2015
Director TitleAgeSince
Director/Board Member 70 31/05/2016
Chairman 74 31/12/2005
Director/Board Member - 30/09/2013
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-16.67%-21.05%-68.09% 5.44M
+0.24%+1.71%+10.73%+82.15% 46.28B
+2.46%+5.97%+51.91%+96.77% 34.73B
+0.35%-2.01%-9.52%+34.04% 11.56B
+1.22%-2.85%+12.12%+93.88% 11.32B
+0.57%+3.33%+39.31%+130.57% 9.27B
-0.08%+1.20%+13.26%+41.20% 7.13B
+1.22%+1.77%+44.21%-17.25% 6.6B
+0.81%+0.44%+29.73%+236.35% 6.39B
-0.63%-3.58%-37.81%-7.82% 4.98B
Average +0.62%-0.60%+13.29%+62.18% 13.83B
Weighted average by Cap. +0.93%+1.07%+22.27%+83.03%

Financials

2024 2025
Net sales 5.09M 3.6M 3.1M 2.85M 2.69M 5.05M 340M 33.83M 13.17M 167M 13.51M 13.22M 577M 1.19M 841K 726K 667K 628K 1.18M 79.39M 7.91M 3.08M 38.96M 3.16M 3.09M 135M
Net income -5.8M -4.1M -3.54M -3.25M -3.06M -5.75M -387M -38.54M -15M -190M -15.39M -15.06M -657M -5.94M -4.2M -3.63M -3.33M -3.14M -5.9M -397M -39.5M -15.38M -195M -15.77M -15.44M -673M
Net Debt 759K 537K 463K 426K 401K 753K 50.64M 5.04M 1.96M 24.85M 2.01M 1.97M 85.97M 2.77M 1.96M 1.69M 1.55M 1.46M 2.75M 185M 18.42M 7.17M 90.76M 7.35M 7.2M 314M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
18/06/26 0.0150 $ 0.00% 984,767
17/06/26 0.0150 $ -11.76% 1,046,254
16/06/26 0.0170 $ +6.25% 1,027,700
15/06/26 0.0160 $ -5.88% 124,024
12/06/26 0.0170 $ -5.56% 2,127,316

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!